WCN26-9488 Cardiorenal protective effect of SGLT2i empagliflozin in a novel mouse model of uremic cardiomyopathy via regulating the Nrf2-mediated oxidative stress

Uremic cardiomyopathy (UCM), characterized by left ventricular hypertrophy, myocardial fibrosis, and predominant diastolic dysfunction, is a major contributor to cardiovascular mortality in end-stage renal disease (ESRD). Progress in mechanistic and therapeutic research has been hindered by the lack of preclinical models that faithfully reproduce the integrated cardiac and renal phenotype observed in patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protective effects in chronic kidney disease beyond glycemic control; however, their therapeutic relevance to UCM remains largely unexplored.